Skip to content

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Publications, Papers and Posters

Poster: Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

October 6, 2018

Poster presented at ESMO 2018

Poster: Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies

June 6, 2018

Poster presented at ASCO 2018

Poster: Tumor cell death caused by INT230-6 induces protective T cell immunity

April 6, 2017

Poster presented at AACR 2017

Poster: Intratumoral injection of INT230-6 induces protective T cell immunity

November 6, 2016

Poster presented at SITC 2016

Poster: A novel immunotherapy, INT230-6, is able to induce high rates of complete and durable response in mice through a cytotoxic T-cell-dependent mechanism

April 18, 2016

Poster presented at AACR 2016

Poster: Novel Drug, INT230-6 shows strong synergy with anti-PD-1 Antibodies and can induce high complete response rates with T-cell memory response in a colon cancer mouse model

November 11, 2015

Poster presented at SITC 2015

Poster: INT230-6, a Novel Intratumoral Anticancer Agent, is able to Eradicate Large Established Tumors and Stimulate Potent Antitumor Immunity

April 19, 2015

Poster presented at AACR 2015

Poster: Novel cell penetrating formulation of cytotoxic agents administered intratumorally causes complete regression of large tumors and stimulation of an adaptive immune response in BALB/c syngeneic mice inoculated subcutaneously with murine CT26 colon cancer

October 9, 2014

Poster presented at National Cancer Institute Immunology and Immunotherapy Meeting, October 2014

« Previous Page1 Page2 Next »

Privacy Policy

Menu

Privacy Policy

© 2021 Intensity Therapeutics. All rights reserved.

Linkedin Twitter